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Summary Results of several clinically relevant studies
were presented at the 2016 Annual Meeting of the Eu-
ropean Society of Medical Oncology (ESMO). This ar-
ticle summerizes the personal highlights of threemed-
ical oncologists in their respective areas of expertise.
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The 2016 Annual Meeting of the European Society of
Medical Oncology (ESMO) was characterized by an
abundance of presentations of novel and potentially
practice-changing clinical trial results never seen be-
fore at a European cancer conference. This clearly
underlines the importance of this meeting among the
plethora of other oncology congresses. Within this
huge amount of data, two main trends were observed:
Immunotherapy with immune checkpointmodulators
is still at the very center of scientific interest with fur-
ther treatment individualization being a second main
emphasis.
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This short review reflects the personal highlights of
three experts in medical oncology in their respective
fields of expertise.
Dr. Dediu: My personal highlights of ESMO 2016:
a) Paradigm-changing data: Ipilimumab was superior
to placebo [1] as adjuvant therapy of malignant
melanoma while pembrolizumab was better than
chemotherapy as first-line therapy in non-small-
cell lung cancer (NSCLC) with ≥50% PD-L1 expres-
sion without EGFR mutation or ALK translocation
[2], for both in terms of overall survival.
b) Data-confirming important previous advances: Ad-
dition of the CDK4/6 inhibitor ribociclib to the aro-
matase-inhibitor (AI) letrozole as first-line therapy
in estrogen-receptor (ER)-positive HER2-negative
patients with advanced breast cancer yielded su-
perior progression-free survival (PFS) data over
endocrine therapy alone [3]. Niraparib, a novel
PARP inhibitor, prolonged PFS when used as main-
tenance therapy in platinum-sensitive ovarian can-
cer irrespective of the presence or absence of BRCA
germline mutations [4]. Atezolizumab, a mono-
clonal antibody targeting PD-L1, was successfully
tested as second- and third-line therapy in NSCLC
[5] while other immune checkpoint modulators
such as pembrolizumab [6] and nivolumab [7]
showed promising results in advanced urothelial
cancer.
c) Promising data that should await further confirma-
tion before being translated into the clinical routine
setting: Sunitinib was superior to placebo as ad-
juvant treatment of renal cell cancer (RCC) [8];
furthermore, cabozantinib was superior to suni-
tinib as first-line therapy of metastatic RCC [9].
Finally, the anti-estrogen fulvestrant was superior
to the AI anastrozole as first-line therapy in ER-pos-
itive metastatic breast cancer although this benefit
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was apparently restricted to patients with visceral
metastases [10].
Dr. Gerger: Colorectal cancer “sidedness”:
Colorectal cancer is a heterogeneous disease. In
contrast to the left-sided colon, which derives from
the embryonic hindgut, the right-sided colon origi-
nates from the midgut.
Primary tumors arising from different regions of
the colon are molecularly and clinically distinct. Left-
sided tumors more frequently possess a molecular
profile of an EGFR inhibitor-sensitive phenotype,
which is reflected in EGFR/ERB-B2 and epiregulin
amplification; conversely, right-sided tumors show
more frequently BRAF mutations and microsatellite
instability. These molecular differences manifest in
different clinical behavior, with right-sided tumors
harboring a worse prognosis. At this year’s ESMO
conference in Copenhagen, the predictive value of
colon cancer sidedness was comprehensively dis-
cussed including retrospective analyses of the anti-
VEGF versus anti-EGFR head-to-head trials FIRE-3,
PEAK, and CALGB80405 [11]. In summary, in first-
line therapy of patients with left-sided RAS wild-type
tumors, a combination therapy consisting of an EGFR
antibody with chemotherapy is recommended. In pa-
tients with right-sided RAS wild-type tumors, there is
presently no proven benefit of an EGFR antibody com-
pared with bevacizumab. Therefore, a bevacizumab
plus chemotherapy combination is recommended.
Dr. Zojer: My personal highlights of ESMO 2016:
Apart from the seminal results of the KEYNOTE-
024 and CheckMate-026 lung cancer trials, the follow-
ing two presentations seem to have practice-chang-
ing impact: Mirza et al. [4] reported results from
a randomized double-blind phase 3 trial of mainte-
nance therapy with the PARP inhibitor niraparib ver-
sus placebo (2:1) in patients with platinum-sensitive
recurrent ovarian cancer (ENGOT-OV16/NOVA trial).
Overall, 553 patients were enrolled after response to
platinum chemotherapy, 203 with a germline BRCA
mutation and 350 patients without such a mutation.
Interestingly, niraparib maintenance improved out-
come in terms of PFS not only in the patient co-
hort with BRCA mutation (PFS, 21.0 months versus
5.5 months; p < 0.0001) but also in the BRCA wild-
type subset (PFS, 9.3 months versus 3.9 months, p <
0.0001). Although overall outcome was better in the
mutant subset, these results seem to indicate that
PARP inhibition is an effective treatment modality for
ovarian cancer independent of germline BRCA muta-
tion status. Important results were also reported on
the adjuvant treatment of stage III melanoma. Egger-
mont et al. [1] showed that ipilimumab not only pro-
longed relapse-free survival in this setting, but also led
to an improvement in terms of overall survival com-
pared with placebo (5-year overall survival 65.4% ver-
sus 54.4%; p = 0.001; EORTC 18071 trial).
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